Allogene Therapeutics (ALLO) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Allogene Therapeutics (NASDAQ: ALLO):

• 4/16/2026 – Allogene Therapeutics was upgraded by JPMorgan Chase & Co. from “underweight” to “neutral”.
• 4/14/2026 – Allogene Therapeutics had its price target raised by Sanford C. Bernstein from $1.60 to $3.85. They now have a “market perform” rating on the stock.
• 4/14/2026 – Allogene Therapeutics had its price target raised by HC Wainwright from $8.00 to $12.00. They now have a “buy” rating on the stock.
• 4/14/2026 – Allogene Therapeutics had its “outperform” rating reaffirmed by Citigroup Inc..
• 4/14/2026 – Allogene Therapeutics had its price target raised by Argus from $1.60 to $3.85. They now have a “market perform” rating on the stock.
• 4/14/2026 – Allogene Therapeutics had its price target raised by Citizens Jmp from $5.00 to $8.00. They now have a “market outperform” rating on the stock.
• 4/14/2026 – Allogene Therapeutics had its price target raised by Robert W. Baird from $7.00 to $9.00. They now have an “outperform” rating on the stock.
• 4/13/2026 – Allogene Therapeutics had its price target raised by Jefferies Financial Group Inc. from $6.00 to $10.00. They now have a “buy” rating on the stock.
• 4/10/2026 – Allogene Therapeutics is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $6.00 price target on the stock.
• 3/25/2026 – Allogene Therapeutics was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/13/2026 – Allogene Therapeutics had its “buy” rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.
• 3/13/2026 – Allogene Therapeutics had its price target raised by Piper Sandler from $7.00 to $8.00. They now have an “overweight” rating on the stock.
• 2/22/2026 – Allogene Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Buying and Selling

In other news, EVP Zachary Roberts sold 35,700 shares of Allogene Therapeutics stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $1.77, for a total value of $63,189.00. Following the completion of the transaction, the executive vice president owned 581,166 shares in the company, valued at approximately $1,028,663.82. The trade was a 5.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Earl Martin Douglas sold 22,900 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $1.76, for a total transaction of $40,304.00. Following the completion of the sale, the senior vice president directly owned 564,948 shares in the company, valued at approximately $994,308.48. This represents a 3.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 278,452 shares of company stock worth $534,053 in the last 90 days. Company insiders own 13.20% of the company’s stock.

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.